{"id":41811,"date":"2025-09-18T15:54:47","date_gmt":"2025-09-18T07:54:47","guid":{"rendered":"https:\/\/flcube.com\/?p=41811"},"modified":"2025-09-18T15:54:48","modified_gmt":"2025-09-18T07:54:48","slug":"suzhou-zelgen-secures-nmpa-approval-for-zggs34-trites-targeting-muc17%e2%80%91positive-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41811","title":{"rendered":"Suzhou Zelgen Secures NMPA Approval for ZGGS34 TriTEs Targeting MUC17\u2011Positive Solid Tumors"},"content":{"rendered":"\n<p><strong>Suzhou Zelgen Biopharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688266:SHA\">SHA: 688266<\/a>) announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has approved its clinical trial of <strong>ZGGS34 for Injection<\/strong>. The drug, a <strong>trispecific T\u2011cell engager (TriTE)<\/strong> that simultaneously binds <strong>CD3<\/strong>, <strong>CD28<\/strong>, and the tumor\u2011associated antigen <strong>MUC17<\/strong>, is slated for use in patients with <strong>MUC17\u2011positive advanced solid tumors<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-makes-zggs34-a-breakthrough\">What Makes ZGGS34 a Breakthrough<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Trispecific design<\/strong>: By engaging both T\u2011cell costimulatory (CD28) and activation (CD3) pathways while anchoring to MUC17, ZGGS34 orchestrates a potent, tumor\u2011centric immune response.<\/li>\n\n\n\n<li><strong>Once\u2011daily, subcutaneous dosing<\/strong>: The injectable formulation offers a patient\u2011friendly alternative to traditional intravenous biologics.<\/li>\n\n\n\n<li><strong>Broad tumor coverage<\/strong>: Preclinical panels spanning colorectal, pancreatic, and ovarian cancers all demonstrated significant tumor regression.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-preclinical-and-safety-profile\">Preclinical and Safety Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Tumor\u2011inhibitory activity<\/strong>: In murine xenograft models, ZGGS34 induced complete or near\u2011complete tumor regression at doses below 0.1\u202fmg\/kg.<\/li>\n\n\n\n<li><strong>Favorable safety<\/strong>: Non\u2011human primate toxicology studies revealed no dose\u2011limiting toxicities, with cytokine profiles comparable to other T\u2011cell engager platforms.<\/li>\n\n\n\n<li><strong>Immune activation<\/strong>: Flow cytometry confirmed robust T\u2011cell proliferation and cytokine release specifically within the tumor microenvironment, minimizing systemic exposure.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-this-means-for-the-market\">What This Means for the Market<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011in\u2011class approval<\/strong>: The NMPA clearance positions Zelgen as a pioneer in the emerging TriTE space, potentially attracting partnerships with global oncology leaders.<\/li>\n\n\n\n<li><strong>Addressing unmet need<\/strong>: MUC17 is overexpressed in >70\u202f% of advanced solid tumors, yet targeted therapies remain scarce. ZGGS34 could fill a critical therapeutic niche.<\/li>\n\n\n\n<li><strong>Pipeline momentum<\/strong>: With the trial approval secured, Zelgen can accelerate Phase\u202fII enrollment and lay groundwork for eventual global IND submissions.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-forward-outlook\">Forward Outlook<\/h2>\n\n\n\n<p>Suzhou\u202fZelgen plans to initiate the first\u2011in\u2011human Phase\u202fII study later this year, enrolling up to 120 MUC17\u2011positive patients across 10 sites nationwide. Should the early data mirror preclinical promise, the company anticipates a potential breakthrough that could reshape the treatment paradigm for advanced solid tumors.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/688266_20250918_JK27-2.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688266_20250918_JK27.\"><\/object><a id=\"wp-block-file--media-9bff7e10-30a2-4acb-8bec-9e170c2900a9\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/688266_20250918_JK27-2.pdf\">688266_20250918_JK27<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/688266_20250918_JK27-2.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-9bff7e10-30a2-4acb-8bec-9e170c2900a9\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that the National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":41819,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,905,246],"class_list":["post-41811","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-sha-688266","tag-zelgen-biopharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Suzhou Zelgen Secures NMPA Approval for ZGGS34 TriTEs Targeting MUC17\u2011Positive Solid Tumors - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that the National Medical Products Administration (NMPA) has approved its clinical trial of ZGGS34 for Injection. The drug, a trispecific T\u2011cell engager (TriTE) that simultaneously binds CD3, CD28, and the tumor\u2011associated antigen MUC17, is slated for use in patients with MUC17\u2011positive advanced solid tumors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=41811\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Suzhou Zelgen Secures NMPA Approval for ZGGS34 TriTEs Targeting MUC17\u2011Positive Solid Tumors\" \/>\n<meta property=\"og:description\" content=\"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that the National Medical Products Administration (NMPA) has approved its clinical trial of ZGGS34 for Injection. The drug, a trispecific T\u2011cell engager (TriTE) that simultaneously binds CD3, CD28, and the tumor\u2011associated antigen MUC17, is slated for use in patients with MUC17\u2011positive advanced solid tumors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=41811\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-18T07:54:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-18T07:54:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1810.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41811#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41811\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Suzhou Zelgen Secures NMPA Approval for ZGGS34 TriTEs Targeting MUC17\u2011Positive Solid Tumors\",\"datePublished\":\"2025-09-18T07:54:47+00:00\",\"dateModified\":\"2025-09-18T07:54:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41811\"},\"wordCount\":324,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41811#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1810.webp\",\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"SHA: 688266\",\"Zelgen Biopharmaceuticals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41811#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41811\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=41811\",\"name\":\"Suzhou Zelgen Secures NMPA Approval for ZGGS34 TriTEs Targeting MUC17\u2011Positive Solid Tumors - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41811#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41811#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1810.webp\",\"datePublished\":\"2025-09-18T07:54:47+00:00\",\"dateModified\":\"2025-09-18T07:54:48+00:00\",\"description\":\"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that the National Medical Products Administration (NMPA) has approved its clinical trial of ZGGS34 for Injection. The drug, a trispecific T\u2011cell engager (TriTE) that simultaneously binds CD3, CD28, and the tumor\u2011associated antigen MUC17, is slated for use in patients with MUC17\u2011positive advanced solid tumors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41811#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41811\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41811#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1810.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1810.webp\",\"width\":1080,\"height\":608,\"caption\":\"Suzhou\u202fZelgen Secures NMPA Approval for ZGGS34 TriTEs Targeting MUC17\u2011Positive Solid Tumors\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41811#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Suzhou Zelgen Secures NMPA Approval for ZGGS34 TriTEs Targeting MUC17\u2011Positive Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Suzhou Zelgen Secures NMPA Approval for ZGGS34 TriTEs Targeting MUC17\u2011Positive Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","description":"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that the National Medical Products Administration (NMPA) has approved its clinical trial of ZGGS34 for Injection. The drug, a trispecific T\u2011cell engager (TriTE) that simultaneously binds CD3, CD28, and the tumor\u2011associated antigen MUC17, is slated for use in patients with MUC17\u2011positive advanced solid tumors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=41811","og_locale":"en_US","og_type":"article","og_title":"Suzhou Zelgen Secures NMPA Approval for ZGGS34 TriTEs Targeting MUC17\u2011Positive Solid Tumors","og_description":"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that the National Medical Products Administration (NMPA) has approved its clinical trial of ZGGS34 for Injection. The drug, a trispecific T\u2011cell engager (TriTE) that simultaneously binds CD3, CD28, and the tumor\u2011associated antigen MUC17, is slated for use in patients with MUC17\u2011positive advanced solid tumors.","og_url":"https:\/\/flcube.com\/?p=41811","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-18T07:54:47+00:00","article_modified_time":"2025-09-18T07:54:48+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1810.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=41811#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=41811"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Suzhou Zelgen Secures NMPA Approval for ZGGS34 TriTEs Targeting MUC17\u2011Positive Solid Tumors","datePublished":"2025-09-18T07:54:47+00:00","dateModified":"2025-09-18T07:54:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=41811"},"wordCount":324,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=41811#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1810.webp","keywords":["Cancer","Clinical trial approval \/ initiation","SHA: 688266","Zelgen Biopharmaceuticals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=41811#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=41811","url":"https:\/\/flcube.com\/?p=41811","name":"Suzhou Zelgen Secures NMPA Approval for ZGGS34 TriTEs Targeting MUC17\u2011Positive Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=41811#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=41811#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1810.webp","datePublished":"2025-09-18T07:54:47+00:00","dateModified":"2025-09-18T07:54:48+00:00","description":"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that the National Medical Products Administration (NMPA) has approved its clinical trial of ZGGS34 for Injection. The drug, a trispecific T\u2011cell engager (TriTE) that simultaneously binds CD3, CD28, and the tumor\u2011associated antigen MUC17, is slated for use in patients with MUC17\u2011positive advanced solid tumors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=41811#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=41811"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=41811#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1810.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1810.webp","width":1080,"height":608,"caption":"Suzhou\u202fZelgen Secures NMPA Approval for ZGGS34 TriTEs Targeting MUC17\u2011Positive Solid Tumors"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=41811#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Suzhou Zelgen Secures NMPA Approval for ZGGS34 TriTEs Targeting MUC17\u2011Positive Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1810.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41811","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41811"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41811\/revisions"}],"predecessor-version":[{"id":41820,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41811\/revisions\/41820"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/41819"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41811"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41811"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41811"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}